Related Experiment Video

Updated: Dec 9, 2025

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

2.9K

Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer

Wei Wen1,2, Ernest S Han1, Thanh H Dellinger1

  • 1Department of Surgery, City of Hope National Med Center, Duarte, CA 91010, USA.

Cancers
|September 15, 2020
PubMed

Insights

Combining targeted drugs like sunitinib, dasatinib, and everolimus shows promise for advanced ovarian cancer. This triple therapy effectively inhibits multiple cancer growth pathways, improving outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Advanced and recurrent ovarian cancer require more effective therapies.
  • Single targeted agents show limited success due to pathway compensation.
  • Combination therapy is a promising strategy to overcome drug resistance.

Purpose of the Study:

  • To investigate the efficacy of combining FDA-approved targeted drugs in human ovarian cancer.
  • To evaluate the synergistic anti-tumor activity of sunitinib, dasatinib, and everolimus.
  • To assess the impact of this combination on key signaling pathways and tumor growth.

Main Methods:

  • Utilized a combination of sunitinib (tyrosine kinase inhibitor), dasatinib (SRC inhibitor), and everolimus (mTOR inhibitor).
  • Assessed anti-tumor activity in human ovarian cancer cells and in mouse models.
  • Analyzed the effects on STAT3, SRC, MAPK, and AKT signaling pathways.
  • Evaluated the combination's synergy with paclitaxel.

Main Results:

  • Sunitinib and dasatinib demonstrated synergistic anti-tumor activity by inhibiting STAT3, SRC, and MAPK pathways.
  • Adding everolimus further enhanced anti-tumor activity and inhibited the PI3K/AKT/mTOR pathway.
  • The triple combination significantly inhibited ovarian tumor growth in mice.
  • Combined treatment synergistically increased the efficacy of paclitaxel both in vitro and in vivo.

Conclusions:

  • Simultaneous inhibition of multiple signaling pathways offers superior anti-tumor activity compared to single-pathway inhibition.
  • This multi-targeted drug combination represents a potential therapeutic strategy for ovarian cancer.
  • The triple combination therapy warrants further investigation for clinical application in ovarian cancer patients.
Keywords:
combinationdasatinibeverolimusovarian cancersunitinibtargeted therapy

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.5K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K